01-Nov-2026 14:20:01

EVONILE PHARMA : RIGHTS ISSUE WORTH UP TO RS 900 CR GETS BSE IN-PRINCIPLE APPROVAL

• Company received BSE in-principle approval on October 30, 2026 for the proposed rights issue • Rights issue of partly paid equity shares for an aggregate amount not exceeding ₹900 Cr • Board meeting on November 4, 2026 to consider and approve the Letter of Offer • Rights Issue Committee on the same date to decide issue price, entitlement ratio, record date and fractional entitlement Impact: Neutral (Procedural approval received; issue price and entitlement ratio are yet to be determined)

Novartis India Ltd

← Back to feed